A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Open Access
- 26 December 2018
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 120 (3) , 286-293
Abstract
This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor pimasertib administered orally once daily (QD) or twice daily (BID) in locally advanced or metastatic solid tumours (NCT01985191). Patients with locally advanced or metastatic solid tumours with documented wild-type TP53 and RAS or RAF mutations were enroled. A 3 + 3 dose-escalation design was employed. The primary objective was to assess maximum tolerated dose (MTD). Twenty-six patients were treated with SAR405838 200 or 300 mg QD plus pimasertib 60 mg QD or 45 mg BID. The MTD was SAR405838 200 mg QD plus pimasertib 45 mg BID. The most common dose-limiting toxicity was thrombocytopenia. The most frequently occurring treatment-related adverse events were diarrhoea (81%), increased blood creatine phosphokinase (77%), nausea (62%) and vomiting (62%). No significant drug–drug interactions were observed. The biomarkers MIC-1 and pERK were, respectively, upregulated and downregulated in response to study treatment. In 24 efficacy-evaluable patients, one patient (4%) had a partial response and 63% had stable disease. The safety profile of SAR405838 and pimasertib combined was consistent with the safety profiles of both drugs. Preliminary antitumour activity was observed.Keywords
Funding Information
- Sanofi
This publication has 20 references indexed in Scilit:
- Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesisExperimental Hematology, 2014
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I TrialEuropean Journal of Cancer, 2012
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Targeting mitogen-activated protein kinase kinase (MEK) in solid tumorsTargeted Oncology, 2009
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Targeting the mitogen-activated protein kinase cascade to treat cancerNature Reviews Cancer, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003